Monte Rosa Therapeutics vs Tonix Pharmaceuticals Holding
Monte Rosa Therapeutics is the larger business, with $124m of revenue in fiscal 2025 against $13.1m for Tonix Pharmaceuticals Holding (9.4 times as much). Monte Rosa Therapeutics grew faster (63.5% against 29.8%). Monte Rosa Therapeutics kept more of each dollar of sales as profit: a net margin of -31.2% against -946.2%.
| Latest fiscal year | Monte Rosa TherapeuticsGLUE, 2025 | Tonix Pharmaceuticals HoldingTNXP, 2025 |
|---|---|---|
| Revenue | $124m | $13.1m |
| Revenue growth | 63.5% | 29.8% |
| Net income | −$38.6m | −$124m |
| Operating margin | -43.8% | — |
| Net margin | -31.2% | -946.2% |
| Return on equity | -16.9% | -64.5% |
| Free cash flow | −$27.5m | −$103m |
| Cash | $130m | $208m |
| Total debt | $0 | — |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | 0.0% | — |
| Share buybacks | — | $13.8m |
| Employees | 150 | 142 |
| Market value | $894m | $86.9m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 37 sales | 7 buys, 0 sales |